Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 20243-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#20243-1-AP, RRID:AB_10697656
- Product name
- YES1-Specific antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated YES1-Specific antibody (Cat. #20243-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IHC, IP, WB, ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references A brain proteomic signature of incipient Alzheimer's disease in young APOE ε4 carriers identifies novel drug targets.
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
MiR-17-5p up-regulates YES1 to modulate the cell cycle progression and apoptosis in ovarian cancer cell lines.
Roberts JA, Varma VR, An Y, Varma S, Candia J, Fantoni G, Tiwari V, Anerillas C, Williamson A, Saito A, Loeffler T, Schilcher I, Moaddel R, Khadeer M, Lovett J, Tanaka T, Pletnikova O, Troncoso JC, Bennett DA, Albert MS, Yu K, Niu M, Haroutunian V, Zhang B, Peng J, Croteau DL, Resnick SM, Gorospe M, Bohr VA, Ferrucci L, Thambisetty M
Science advances 2021 Nov 12;7(46):eabi8178
Science advances 2021 Nov 12;7(46):eabi8178
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E, Garmendia I, Lozano T, Serrano D, Senent Y, Redrado M, Villalba M, De Andrea CE, Exposito F, Ajona D, Ortiz-Espinosa S, Remirez A, Bertolo C, Sainz C, Garcia-Pedrero J, Pio R, Lasarte J, Agorreta J, Montuenga LM, Calvo A
Journal for immunotherapy of cancer 2021 Mar;9(3)
Journal for immunotherapy of cancer 2021 Mar;9(3)
YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
Garmendia I, Pajares MJ, Hermida-Prado F, Ajona D, Bértolo C, Sainz C, Lavín A, Remírez AB, Valencia K, Moreno H, Ferrer I, Behrens C, Cuadrado M, Paz-Ares L, Bustelo XR, Gil-Bazo I, Alameda D, Lecanda F, Calvo A, Felip E, Sánchez-Céspedes M, Wistuba II, Granda-Diaz R, Rodrigo JP, García-Pedrero JM, Pio R, Montuenga LM, Agorreta J
American journal of respiratory and critical care medicine 2019 Oct 1;200(7):888-899
American journal of respiratory and critical care medicine 2019 Oct 1;200(7):888-899
MiR-17-5p up-regulates YES1 to modulate the cell cycle progression and apoptosis in ovarian cancer cell lines.
Li L, He L, Zhao JL, Xiao J, Liu M, Li X, Tang H
Journal of cellular biochemistry 2015 Jun;116(6):1050-9
Journal of cellular biochemistry 2015 Jun;116(6):1050-9
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- human placenta tissue were subjected to SDS PAGE followed by western blot with 20243-1-AP(YES1-Specific antibody) at dilution of 1:300
- Sample type
- tissue
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human colon using 20243-1-AP(YES1-Specific antibody) at dilution of 1:50 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The YES1-Specific antibody from Proteintech is a rabbit polyclonal antibody to a peptide of human YES1-Specific. This antibody recognizes human, mouse, rat antigen. The YES1-Specific antibody has been validated for the following applications: ELISA, WB, IHC analysis.
